|

Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer

RECRUITINGSponsored by Peking University People's Hospital
Actively Recruiting
SponsorPeking University People's Hospital
Started2021-09-01
Est. completion2025-08-31
Eligibility
Age17 Years – 45 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05647109

Summary

To construct a prediction model of progesterone sensitivity in patients with endometrial cancer treated with fertility preservation

Eligibility

Age: 17 Years – 45 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Have a confirmed pathological diagnosis based upon hysteroscopy: atypical endometrial hyperplasia or histologically prove well-differentiated EEC G1 without myometrial invasion
* No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound
* Have a desire for remaining reproductive function or uterus
* Good compliance with adjunctive treatment and follow-up

Exclusion Criteria:

* Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
* Pregnancy or potential pregnancy
* Confirmed diagnosis of any cancer in reproductive system
* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
* Hypersensitivity or contradiction for using MPA or MA
* With other factors of reproductive dysfunction;
* Strong request for uterine removal or other conservative treatment

Conditions3

Atypical Endometrial HyperplasiaCancerEndometrial Carcinoma Stage I

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.